These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22074479)

  • 1. Epidermal growth factor receptors: a functional perspective.
    Mitrasinovic PM
    Curr Radiopharm; 2012 Jan; 5(1):29-33. PubMed ID: 22074479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the ERBB family in cancer: couples therapy.
    Tebbutt N; Pedersen MW; Johns TG
    Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in structure-based design of EGFR inhibitors.
    Mitrasinovic PM
    Curr Drug Targets; 2013 Jun; 14(7):817-29. PubMed ID: 23547755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory activity against epidermal growth factor receptor (EGFR) based on single point mutations of active site residues.
    Mitrasinovic PM
    Med Chem; 2014 May; 10(3):252-70. PubMed ID: 23628078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Gainet M; Guardiola E; Dufresne A; Pivot X
    Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor pathway inhibitors.
    Baselga J; Cortes J
    Cancer Chemother Biol Response Modif; 2005; 22():205-23. PubMed ID: 16110613
    [No Abstract]   [Full Text] [Related]  

  • 11. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
    Kim ES
    Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
    Kuo T; Fisher GA
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ErbB inhibitors in trastuzumab resistance.
    Miller KD
    Oncologist; 2004; 9 Suppl 3():16-9. PubMed ID: 15163843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.